American Diabetes Association
Browse

Genetics of C-peptide and Age at Diagnosis in Type 1 Diabetes

Download (1.65 MB)
figure
posted on 2024-11-18, 21:40 authored by Delnaz Roshandel, Athina Spiliopoulou, Stuart J. McGurnaghan, Andrii Iakovliev, Debby Lipschutz, Caroline Hayward, Shelley B. Bull, Barbara E.K. Klein, Kris E. Lee, Gregory L. Kinney, Marian Rewers, Tina Costacou, Rachel G. Miller, Paul M. McKeigue, Andrew D. Paterson, Helen M. Colhoun

Identified genetic loci for C-peptide and age at diagnosis (AAD) in individuals with type 1 diabetes (T1D) explain only a small proportion of their variation. Here, we aimed to perform large metagenome-wide association studies (GWAS) of C-peptide and AAD in T1D; and to identify the HLA allele/haplotypes associated with C-peptide and AAD. 7,252 and 7,923 European individuals with T1D were included in C-peptide and AAD GWAS, respectively. HLA-DQB1*06:02 which is strongly protective against T1D was associated with higher C-peptide. HLA-DQB1*03:02, HLADRB1*03:01 and HLA-A*24:02 which increase T1D risk were independently associated with younger AAD. HLA-DR3-DR4 haplotype combination, the strongest T1D susceptibility factor, was associated with younger AAD. Outside HLA region, rs115673528 on Chr5 (GABRG2) was associated with C-peptide, and an indel, rs111970692, on Chr15 within CTSH, a known T1D locus, was associated with AAD. Genetically predicted CTSH expression, methylation and protein levels were associated with AAD; Mendelian randomization analysis suggested that higher levels of procathepsin H reduce AAD. In conclusion, some HLA allele/haplotypes associated with T1D also contribute to variability of C-peptide and AAD. Outside HLA, T1D loci are generally not associated with C-peptide or AAD. CTSH could be a potential therapeutic target to delay development/progression of type 1 diabetes.

Funding

This study was supported by research grant from the Medical Research Council (MR/T032340/1) and UK-Canada Diabetes Research Team Grant (UCD-170583) from CIHR. The establishment of the SDRN Type 1 Bioresource was supported by the Chief Scientist Office of the Scottish Government Health Directorates (ETM/47), by Diabetes UK (10/0004010), and by in-kind contributions from the Scottish Diabetes Research Network. Genotyping was supported by the Juvenile Diabetes Research Fund (17-2013-7). Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006). The development of the GENOSCORES platform was supported by a Springboard Award (SBF006/1109) from the Academy of Medical Sciences, supported in turn by the Wellcome Trust, the UK Government Department of Business, Energy and Indus- trial Strategy, the British Heart Foundation, and Diabetes UK. CH was supported by an MRC Human Genetics Unit programme grant ‘Quantitative traits in health and disease’ (U. MC_UU_00007/10). The CACTI study was funded by NIH grants P30 DK057516/DK/NIDDK, R01 HL113029/HL/NHLBI, R01 HL079611/HL/NHLBI, UL1 TR002535/TR/NCATS, P30 DK116073/DK/NIDDK, M01 RR000051/RR/NCRR, and R01 HL061753/HL/NHLBI. EDC is funded by NIH grant R01-DK034818/DK/NIDDK and by the Rossi Memorial Fund.

History

Usage metrics

    Diabetes

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC